It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Membrane proteins are among the most sought-after yet challenging targets in structural biology and drug discovery.
At Sygnature Discovery, we have a dedicated team with deep expertise and a proven track record in membrane protein production. From construct design to final validation, we deliver tailored solutions for structural, binding, and functional studies.
Our workflows are data-driven and optimized for stability, homogeneity, and downstream compatibility. Because membrane protein projects often require extra problem-solving, we prioritize early feedback and open communication. At every stage, we share data and recommendations so you can make informed decisions quickly.
Supporting your Research
We help you navigate the complexity of membrane proteins with bespoke screening, production, and stabilization strategies. Our approach combines construct design, small-scale screening, and feasibility studies to identify the best expression system and solubilization method for your target. Our team has successfully produced many pharmacologically important integral membrane proteins, including:
• GPCRs (active complexes and inactive receptors)
• Solute Transporters
• Ion Channels
• ABC Transporters
• Receptors
Successful candidates are scaled up to deliver high-quality protein in formats suited to your downstream needs including detergent, nanodisc, co-polymer, and liposomes.
Validation & Characterization
Quality control is built into every step. In addition to standard purity and concentration checks, we offer specialized assays such as:
• Biophysical analysis (FIDA, analytical SEC with HPLC)
• Thermostability testing (TSA)
Membrane Protein-Specific Capabilities
• Dedicated team with extensive experience in membrane protein production and characterization
• Advanced biophysical techniques: TSA (dye-based nanoDSF), size in solution (FIDA), and FSEC for construct screening (HPLC)
• Expertise in preparing membrane proteins for cryo-EM and solving structures
• Proven ability to work with all main membrane mimetics: detergents, nanodisc, co-polymer, and liposomes
• Specialized equipment and software:
o IMPROvER for stability prediction
o Ultracentrifuges (Beckman Optima benchtop and floorstanding)
o LCP capable crystallisation Mosquito
o FIDA instrument with UV and fluorescence detector
o HPLC system with UV and fluorescence detector
Hear From One of our Experts
Our specialist team of membrane protein experts have extensive experience tackling some of the most challenging targets. Production of high-quality membrane protein reagents allow us to drive transformative insights and solutions in drug discovery and biotechnology for our customers.
FIDA (Flow-Induced Dispersion Analysis) allows rapid measurement of protein size in solution and can be…
Posters
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Main home page for the Protein Science and Structural Biology Department. We take time to understand your target and the ultimate aims of the project and tailor our approach accordingly.
At Sygnature we have a dedicated Protein Expression team with expertise across various E. coli, insect cells and mammalian (HEK and CHO) host cell lines.
Comprehensive ion channel assays and bespoke cell lines deliver high-fidelity screening and safety insights, accelerating hit-to-lead and optimization.
Advanced transporter assays and electrophysiology deliver robust, high-throughput data for hit identification, validation, and lead optimization in drug discovery.
